Covid 19 Research using Clinical Trials (Home Page)
HP:0001395: Hepatic fibrosisHPO
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (0)
| Name (Synonyms) | Correlation |
|---|
Correlated MeSH Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D008103 | Liver Cirrhosis, NIH | 1.00 |
| D005355 | Fibrosis NIH | 0.71 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 Clinical Characteristics of COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study
COVID-19 pandemic with SARS-CoV-2 infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver cirrhosis are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. The spectrum of disease and factors that influence the disease course in COVID-19 cases with liver cirrhosis are incompletely defined. This muilticentre observational study (COVID-Cirrhosis-CHESS2002) aims to study the clinical characteristics and risk factors associated with specific outcomes in COVID-19 patients with pre-existing liver cirrhosis.
NCT04329559 COVID-19 Liver Cirrhosis MeSH:Liver Cirrhosis Fibrosis
HPO:Cirrhosis Hepatic fibrosis
Primary Outcomes
Description: 7-day, 28-day, 60-day, 180-day and 365-day all-cause mortality of COVID-19 patients with liver cirrhosis
Measure: All-cause mortality of COVID-19 patients with liver cirrhosis Time: From illness onset of COVID-19 to death from any cause, up to 365 days
Secondary Outcomes
Description: 7-day, 28-day, 60-day, 180-day and 365-day liver-related mortality of COVID-19 patients with liver cirrhosis
Measure: Liver-related mortality of COVID-19 patients with liver cirrhosis Time: From illness onset of COVID-19 to death from liver-related cause, up to 365 days
Description: Risk factors (laboratory findings, imaging findings, etc.) associated with specific outcomes (death, etc.) of COVID-19 patients with liver cirrhosis
Measure: Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis Time: From hospital admission to death, up to 365 days
Description: Baseline characteristics (laboratory findings, imaging findings, etc.) of COVID-19 patients with liver cirrhosis
Measure: Baseline characteristics of COVID-19 patients with liver cirrhosis Time: 1 Day
HPO Nodes
HP:0001395: Hepatic fibrosis
Genes 140
TNPO3 DLL4 PKHD1 SLC40A1 TMEM107 NEK1 MET SKIV2L BBS10 DYNC2H1 TCTN2 CEP55 TMEM67 WDR34 CCDC28B PMM2 BBS7 ARHGAP31 IFT122 TNFSF15 CEP290 BBS2 B9D1 IFT27 TCF4 MKS1 BBIP1 INSR B9D2 IQCB1 TTC37 TRIM32 BBS9 IFT172 DOCK6 RBPJ BBS1 ARL6 PKHD1 CC2D2A LZTFL1 HAMP DLL4 CEP164 PNPLA6 SCYL1 MKKS MST1 IFT140 SDCCAG8 TMEM67 INSR INPP5E GLIS3 IFT172 SLC25A13 TRAF3IP1 TMEM67 ABCB4 LIPA DOLK ABCD3 CC2D2A PHKA2 MPI GPR35 WDR19 DCDC2 BBS4 ANKS6 DZIP1L ASL NPHP1 WDR35 NEK8 WDR35 BBS1 AP1S1 TRAF3IP1 POU2AF1 PMM2 TTC8 RPGRIP1L NPHP3 IFT80 PLIN1 WDPCP PEX1 NPHP4 NOP10 HJV WDPCP CYP7B1 TMEM216 BBS5 SDCCAG8 WDR60 NOTCH1 RPGRIP1 NPHP1 CTNNB1 DGUOK PTRH2 NPHP3 RPGRIP1L CEP290 FADD GPD1 TTC37 IL12RB1 IRF5 TMEM67 NHP2 INPP5E MMEL1 INVS TMEM67 CSPP1 IL12A PHKG2 BBS12 SCYL1 MPI AGL TMEM67 ALG9 TMEM231 OFD1 CC2D2A EOGT SPIB RPGRIP1L TALDO1 GPC1 CEP290 C8ORF37 NPHP3 MKS1 SLC40A1 CC2D2A SNP 0
Primary Outcomes
Description: 7-day, 28-day, 60-day, 180-day and 365-day all-cause mortality of COVID-19 patients with liver cirrhosis
Measure: All-cause mortality of COVID-19 patients with liver cirrhosis Time: From illness onset of COVID-19 to death from any cause, up to 365 daysSecondary Outcomes
Description: 7-day, 28-day, 60-day, 180-day and 365-day liver-related mortality of COVID-19 patients with liver cirrhosis
Measure: Liver-related mortality of COVID-19 patients with liver cirrhosis Time: From illness onset of COVID-19 to death from liver-related cause, up to 365 daysDescription: Risk factors (laboratory findings, imaging findings, etc.) associated with specific outcomes (death, etc.) of COVID-19 patients with liver cirrhosis
Measure: Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis Time: From hospital admission to death, up to 365 daysDescription: Baseline characteristics (laboratory findings, imaging findings, etc.) of COVID-19 patients with liver cirrhosis
Measure: Baseline characteristics of COVID-19 patients with liver cirrhosis Time: 1 Day